RE:Down she goes again...Might even go lower than that over the coming months. 4 of it's product lines are not even in Phase 1 clinical trials yet. So we all know how many years that often takes.
The other 2 are more advanced but studies not yet completed.
Unfortunately, unlike so many other cannabis companies, this one is not high on anyone's list. Seeing as they are not growers of cannabis to supply the market but instead trying to bring to market products not far advanced, I can see where it might be some time before this stock appreciates significantly.
But who knows...if you get real positive results out on their two most advanced products maybe that might be enough to lift RVV up for a bit.